1Malinin V, Neville ME, Eagle G, Perkins W, Gupta R. Lung distribution and clearance of low- or high-dose dual-labeled liposomal amikacin for inhalation in rats dosed once daily for 28 days. Poster presented at: 2014 North American Cystic Fibrosis Conference; October 9-11, 2014; Atlanta, Georgia.
2Rose SJ, Neville ME, Gupta R, Bermudez LE (2014) Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection. PLoS ONE 9(9): e108703. doi:10.1371/journal.pone.0108703.
3Crowle AJ, Tsang AY, Vatter AE, May MH. Comparison of 15 laboratory and patient-derived strains of Mycobacterium avium for ability to infect and multiply in cultured human macrophages. J Clin Microbiology. 1986;24(5):812-21.
4Groneberg DA, Eynott PR, Oate T, Lim S, Wu R, Carlstedt I, Nicholson AG, Chung KF. Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung. Respiratory Medicine. 2002;96(2):81-6.
5Bansil R, Turner BS. Mucin structure, aggregation, physiologic functions and biomedical applications. Current Opinion in Colloid and Interface Science. 2006;11(2-3):164-170.
6Boyd A, Chakrabarty AM. Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. J of Industrial Microbiology. 1995;15:162-8.
7Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrobial Agents and Chemotherapy. 1995;39(1):34-9.
8Nichols WW, Dorrington SM, Slack MP, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrobial Agents and Chemotherapy. 1988;32(4):518-23.
9Gordon CA, Hodges NA, Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother. 1988;22(5):667-74.